WO2001035926A3 - An improved pharmaceutical composition for treating male erectile dysfunction - Google Patents

An improved pharmaceutical composition for treating male erectile dysfunction Download PDF

Info

Publication number
WO2001035926A3
WO2001035926A3 PCT/IN2000/000105 IN0000105W WO0135926A3 WO 2001035926 A3 WO2001035926 A3 WO 2001035926A3 IN 0000105 W IN0000105 W IN 0000105W WO 0135926 A3 WO0135926 A3 WO 0135926A3
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical composition
erectile dysfunction
male erectile
improved pharmaceutical
treating male
Prior art date
Application number
PCT/IN2000/000105
Other languages
French (fr)
Other versions
WO2001035926A2 (en
Inventor
Ramakrishna Rao Vallabhaneni
Original Assignee
Natco Pharma Ltd
Ramakrishna Rao Vallabhaneni
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Natco Pharma Ltd, Ramakrishna Rao Vallabhaneni filed Critical Natco Pharma Ltd
Priority to AU30485/01A priority Critical patent/AU3048501A/en
Priority to EP00990872A priority patent/EP1237538A2/en
Priority to CA002391968A priority patent/CA2391968A1/en
Publication of WO2001035926A2 publication Critical patent/WO2001035926A2/en
Publication of WO2001035926A3 publication Critical patent/WO2001035926A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings

Abstract

The invention disclosed in this application relates to a novel pharmaceutical composition containing sildenafil useful for nasal administration for the treatment of male erectile dysfunction due to organic, psychogenic and mixed causes. The composition is also effective in patients with erectile dysfunction due to spinal cord injury. The pharmaceutical composition of the present invention is in the form of a solution or a colloidal dispersion in a pharmaceutical vehicle filled into specially designed dosing device for nasal administration. The invention disclosed in this application also provides a method for preparing the pharmaceutical composition containing sildenafil for nasal application for the treatment of male erectile dysfunction.
PCT/IN2000/000105 1999-11-18 2000-10-24 An improved pharmaceutical composition for treating male erectile dysfunction WO2001035926A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU30485/01A AU3048501A (en) 1999-11-18 2000-10-24 An improved pharmaceutical composition for treating male erectile dysfunction
EP00990872A EP1237538A2 (en) 1999-11-18 2000-10-24 An improved pharmaceutical composition for treating male erectile dysfunction
CA002391968A CA2391968A1 (en) 1999-11-18 2000-10-24 An improved pharmaceutical composition for treating male erectile dysfunction

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1128/MAS/99 1999-11-18
IN1128MA1999 1999-11-18

Publications (2)

Publication Number Publication Date
WO2001035926A2 WO2001035926A2 (en) 2001-05-25
WO2001035926A3 true WO2001035926A3 (en) 2001-12-27

Family

ID=11096782

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2000/000105 WO2001035926A2 (en) 1999-11-18 2000-10-24 An improved pharmaceutical composition for treating male erectile dysfunction

Country Status (4)

Country Link
EP (1) EP1237538A2 (en)
AU (1) AU3048501A (en)
CA (1) CA2391968A1 (en)
WO (1) WO2001035926A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050042177A1 (en) * 2003-07-23 2005-02-24 Elan Pharma International Ltd. Novel compositions of sildenafil free base
US20100184722A1 (en) 2008-12-19 2010-07-22 Shimoda Biotech (Pty) Ltd Inclusion complexes of alpha-cyclodextrin and sildenafil salt
AU2011264941B2 (en) * 2010-06-07 2014-10-16 Suda Ltd Oral spray formulations and methods for administration of sildenafil
RU2611403C1 (en) * 2011-12-05 2017-02-21 Суда Лимитед Compositions in the form of a spray for oral administration and methods of the sildenafil administration
GB2497933B (en) * 2011-12-21 2014-12-24 Londonpharma Ltd Drug delivery technology
ES2475942B1 (en) * 2013-01-11 2015-04-16 Farmalider, S.A. Pharmaceutical composition of sildenafil citrate in the form of an aqueous solution
FR3008618A1 (en) * 2013-07-19 2015-01-23 Univ Paris Curie USE OF COMPOUNDS TO RESTORE THE RESPONSE IN THE LIGHT OF CELLS OF THE RETINA
NO2723977T3 (en) 2014-03-19 2018-03-10
WO2016161397A1 (en) * 2015-04-03 2016-10-06 Insys Development Company, Inc. Sildenafil sublingual spray formulations
EP3331888A4 (en) * 2015-08-03 2019-03-20 Synergistic Therapeutics, LLC Sexual dysfunction therapeutic gel
WO2019182745A1 (en) 2018-03-19 2019-09-26 Bryn Pharma, LLC Epinephrine spray formulations
CN114028348B (en) * 2021-10-09 2022-11-08 南京长澳医药科技有限公司 Sildenafil citrate orally disintegrating tablet and preparation method thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998053819A1 (en) * 1997-05-29 1998-12-03 Mochida Pharmaceutical Co., Ltd. Therapeutic agent for erection failure
EP0967214A1 (en) * 1998-06-22 1999-12-29 Pfizer Limited Intranasal formulations for treating sexual disorders
WO1999066933A1 (en) * 1998-06-25 1999-12-29 New Millennium Pharmaceutical Research, Inc. Nasal administration of sildenafil for the treatment of erectile dysfunction
WO2000007597A1 (en) * 1998-07-31 2000-02-17 Hexal Ag Transmucosal therapeutic system for administering sildenafil

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998053819A1 (en) * 1997-05-29 1998-12-03 Mochida Pharmaceutical Co., Ltd. Therapeutic agent for erection failure
EP0967214A1 (en) * 1998-06-22 1999-12-29 Pfizer Limited Intranasal formulations for treating sexual disorders
WO1999066933A1 (en) * 1998-06-25 1999-12-29 New Millennium Pharmaceutical Research, Inc. Nasal administration of sildenafil for the treatment of erectile dysfunction
WO2000007597A1 (en) * 1998-07-31 2000-02-17 Hexal Ag Transmucosal therapeutic system for administering sildenafil

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BEHL CR ET AL.: "Optimization of systemic nasal drug delivery with pharmaceutical excipients", ADVANCED DRUG DELIVERY REVIEWS, vol. 29, no. 1,2, 5 January 1998 (1998-01-05), Amsterdam, pages 117 - 133, XP000996299 *

Also Published As

Publication number Publication date
AU3048501A (en) 2001-05-30
WO2001035926A2 (en) 2001-05-25
EP1237538A2 (en) 2002-09-11
CA2391968A1 (en) 2001-05-25

Similar Documents

Publication Publication Date Title
WO2001035926A3 (en) An improved pharmaceutical composition for treating male erectile dysfunction
IL195723A (en) Use of p53 inhibitors for the preparation of medicament
WO1999011250A3 (en) Noribogaine in the treatment of pain and drug addiction
WO2004071529A3 (en) Uses of anti-insulin-like growth factor i receptor antibodies
TW371628B (en) Composition for treating condyloma acuminata
HUP0301920A2 (en) Injection composition containing p receptor antagonist and magnesium compound suitable for treating brain, spinal and nerve injury
WO2002041837A3 (en) Treatment of mucositis
PL334656A1 (en) Dosage forms and methods of achieving betterement in cases of erection disorderamong male patients
WO1999064059A3 (en) Use of secretin for the treatment of autism and other neurological, behavioral and immunological disorders
EP1478371A4 (en) Methods and products for enhancing immune responses using imidazoquinoline compounds
WO2002056912A3 (en) Pharmaceutical combination for the treatment of cancer containing a 4-quinazolineamine and another anti-neoplastic agent
WO2005107726A3 (en) Method for the treatment of back pain
WO2005000217A3 (en) Combination therapy for the treatment of dyslipidemia
WO2004004661A3 (en) Boroproline compound combination therapy
MXPA01005511A (en) Hapten-carrier conjugates for treating and preventing nicotine addiction.
CA2420895A1 (en) Method for treating erectile dysfunction and increasing libido in men
WO2004037173A3 (en) Method for treating erectile dysfunction and increasing libido in men
NZ515301A (en) Pharmaceutical product comprising the active substance diamorphine, and its use in a process for treating opiate addiction
ZA200209982B (en) Transdermal therapeutic system for parkinson's disease inducing high plasma levels of rotogotine.
WO2001001972A3 (en) SELECTIVE iGluR5 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF MIGRAINE
EP1108426A3 (en) Use of prostaglandin agonists to treat erectile dysfunction or impotence
AU693833B2 (en) Products containing G-CSF and TNF binding protein
WO2000067723A3 (en) Form of administration for applying in body orifices
WO1999059628A3 (en) Combination therapy for the treatment of tumors
WO2003022213A3 (en) Therapeutic treatments for spinal cord injury via blockade of interleukin-1 receptor

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2391968

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 10130578

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2000990872

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000990872

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Ref document number: 2000990872

Country of ref document: EP